Vascular Health Sciences is Now Fully Authorized to Market and Sell Arterosil and Arterosil HP

Share Article

A joint dismissal of all claims and counterclaims between Vascular Health Sciences and Daniels Health Sciences was granted by U.S. District Court Judge Kenneth M. Hoyt.

Vascular Health Sciences announced today that an out-of-court settlement allows the company to freely market and sell Arterosil and Arterosil HP, and that all claims and counterclaims have been irrevocably dismissed.

In 2012 Daniels Health Sciences, LLC (DHS) sued Vascular Health Sciences, LLC (VHS) in the United States District Court for the Southern District of Texas for breach of contract, misappropriation of trade secrets and trademark violations. At the beginning of the case the court granted a preliminary injunction precluding VHS from selling Arterosil and Arterosil HP until case had concluded. VHS disputed DHS’ claims, and filed counterclaims against DHS. VHS filed a motion with the court asking the court to dismiss DHS’s claims and remove the preliminary injunction, but the parties settled the case before that motion was decided. As part of the settlement both sides agreed to fully dismiss all claims by DHS and counterclaims by VHS, allowing VHS to once again freely market and sell Arterosil and Arterosil HP. The court has now granted the parties’ joint motion, and all claims and counterclaims in the case have been dismissed with prejudice. (Civil Action number 4:12-CV-1896: Order of Dismissal signed April 28, 2014 by Kenneth M. Hoyt, United States District Judge.)

“We are pleased to have brought full and permanent closure to this matter” said Vascular Health Sciences’ President & CEO, Robert Long.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Andrea Ward
Dumela PR
+1 (801) 210 9290
Email >